Condition: Triple-negative Breast Cancer · TNBC - Triple-Negative Breast Cancer · Sponsor: Swiss Cancer Institute
About 10-20% of all individuals with breast cancer have a so-called triple-negative tumor (TNBC). This type of breast cancer has a particularly unfavorable course and a higher mortality rate compared to other forms of breast cancer. Research studies show that it is important for individuals with TNBC to achieve a so-called pathologic complete response (pCR) to treatment. In the phase II study SAKK 66/22, it is being investigated whether the administration of the drug INT230-6 before surgery for breast cancer can increase the rate of pCR in the tumor and affected lymph nodes. The tolerability of INT230-6 as well as other factors such as response to treatment and the possibility of breast-conserving surgery are also being examined.
This description comes directly from the study's public registry record.
Jana Musilova, PhD · +41 31 389 91 91 · trials@swisscancerinstitute.ch
Always discuss trial participation with your own doctor first.
| Tumor Zentrum Aarau | Aarau, Switzerland | Terminated |
| St. Claraspital | Basel, Switzerland | Recruiting |
| EOC - IOSI Ospedale regionale Bellinzona e valli - San Giovanni | Bellinzona, Switzerland | Recruiting |
| Kantonsspital Graubünden | Chur, Switzerland | Recruiting |
| Kantonsspital Baselland | Liestal, Switzerland | Recruiting |
| HOCH Health Ostschweiz | Sankt Gallen, Switzerland | Recruiting |
| TBZO - Tumor- & Brustzentrum Ostschweiz | Sankt Gallen, Switzerland | Terminated |
| Kantonsspital Winterthur | Winterthur, Switzerland | Recruiting |
| Universitätsspital Zürich - Klinik für Gynäkologie | Zurich, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06358573